

## **Approved prescription drug products with therapeutic equivalence evaluations.**

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072933230>

# HathiTrust



[www.hathitrust.org](http://www.hathitrust.org)

**Public Domain, Google-digitized**

[http://www.hathitrust.org/access\\_use#pd-google](http://www.hathitrust.org/access_use#pd-google)

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

HE 20.4210 : 982 / suppl. 1

499-K-3

# CUMULATIVE SUPPLEMENT 1 AUG '82 - SEP '82

The University  
of Michigan  
Pharmacy  
Library

PHARMACY  
3rd ed. 1  
suppl. 1


REFERENCE  
DOES NOT CIRCULATE

SERIAL  
REFERENCE

MAN 24 1983  
THE UNIVERSITY  
OF MICHIGAN  
PHARMACY  
LIBRARY

# APPROVED PRESCRIPTION DRUG PRODUCTS

WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS  
3<sup>RD</sup> EDITION



UNIVERSITY OF MICHIGAN  
LIBRARIES

DEC 2 1982

DEPOSITED BY THE  
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google

Original from  
UNIVERSITY OF MICHIGAN





FOOD AND DRUG ADMINISTRATION  
APPROVED PRESCRIPTION DRUG PRODUCTS  
WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS  
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (\*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >Add> to the left of the line on which new information exists. The >Add> symbol is dropped in subsequent cumulative supplements for that item.



Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

**B. ADDENDUM: DESI Pending List**

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

**II. SPECIAL NOTES**

**A. INDICES AND ABBREVIATIONS:**

**STANDARD TERMS:**

Added Route of Administration: INTRAPERITONEAL

**B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST**

Beginning with this cumulative supplement, categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The format of this report and the categories reported may change from time to time.

### III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

#### DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

#### USE OF REPORT

From the data presented, users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in products as either multisource or single source.

#### Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety or its derivatives (ingredient), either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

#### Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.



REPORT OF COUNTS FOR THE DRUG PRODUCT LIST  
UNIVERSITY OF MICHIGAN

A. COUNTS CUMULATIVE BY QUARTERS

JULY '82

6303

1885 (30%)

4418 (70%)

3456 (54.8%)

954 (15.1%)

8 (0.1%)

DRUG PRODUCTS LISTED

CATEGORIES COUNTED

SINGLE SOURCE

MULTISOURCE (1)

THERAPEUTICALLY EQUIVALENT

NOT THERAPEUTICALLY EQUIVALENT

EXCEPTIONS (2)

NUMBER OF APPLICANTS

303

B. ACTIVITY FOR SUPPLEMENT NUMBER 1 AND CUMULATIVE SINCE JULY '82

CUMULATIVE

AUG-SEPT '82

|    |    |
|----|----|
| 85 | 85 |
| 0  | 0  |
| 0  | 0  |
| 18 | 18 |
| 0  | 0  |
| 0  | 0  |
| 2  | 2  |
| 16 | 16 |
| 67 | 67 |
| 26 | 26 |
| 59 | 59 |

DRUG PRODUCTS ADDED:

NEWLY APPROVED

DESIGN EFFECTIVE

REMARKETED

DRUG PRODUCTS REMOVED:

WITHDRAWN APPROVAL

RX TO OTC SWITCH

DISCONTINUED MARKETING

NET GAIN IN DRUG PRODUCTS

NEW SINGLE SOURCE PRODUCTS

NEW MULTISOURCE DRUG PRODUCTS

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (1.0%, AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS  
 DRUG PRODUCT LIST  
 CUMULATIVE SUPPLEMENT NUMBER 1 / AUGUST '82 & SEPTEMBER '82

1

> ADD > ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

> ADD > TABLET; ORAL  
 > ADD > TALACEN  
 > ADD > STERLING DRUG 650MG;EQ 25MG BASEM

AMINO ACIDS (PAGE 3-6)

> ADD > INJECTABLE; INJECTION  
 > ADD > NOVAMINE 8.5%  
 > ADD > CUTTER LABORATORIES 8.5%  
 > ADD > NOVAMINE 11.4%  
 > ADD > CUTTER LABORATORIES 11.4%  
 > ADD >

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE (PAGE 3-11)

CAPSULE; ORAL  
 DELCOBESE  
 > DLT > /DELCO CHEMICAL/ 1.25MG;1.25MG;1.25MG;1.25MG/  
 > DLT > 2.5MG;2.5MG;2.5MG;2.5MG/  
 > DLT > 3.75MG;3.75MG;3.75MG;3.75MG/  
 > DLT > 5MG;5MG;5MG;5MG/  
 > ADD > LEMMON 1.25MG;1.25MG;1.25MG;1.25MG  
 > ADD > 2.5MG;2.5MG;2.5MG;2.5MG  
 > ADD > 3.75MG;3.75MG;3.75MG;3.75MG  
 > ADD > 5MG;5MG;5MG;5MG

TABLET; ORAL  
 DELCOBESE  
 > DLT > /DELCO CHEMICAL/ 1.25MG;1.25MG;1.25MG;1.25MG/  
 > DLT > 2.5MG;2.5MG;2.5MG;2.5MG/  
 > DLT > 3.75MG;3.75MG;3.75MG;3.75MG/  
 > DLT > 5MG;5MG;5MG;5MG/  
 > ADD > LEMMON 1.25MG;1.25MG;1.25MG;1.25MG  
 > ADD > 2.5MG;2.5MG;2.5MG;2.5MG  
 > ADD > 3.75MG;3.75MG;3.75MG;3.75MG  
 > ADD > 5MG;5MG;5MG;5MG

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL  
 > DLT > /PROPOXYPHENE HCL COMPOUND 65/  
 > DLT > /AA/ /ROXANE LABORATORIES/ 22.7MG;32.4MG;16.2MG;6.5MG/

> ADD > AZLOCILLIN SODIUM (PAGE 3-17)

> ADD > INJECTABLE; INJECTION  
 > ADD > AZLIN  
 > ADD > MILES PHARMS/MILES EQ 2GM BASE/VIALM  
 > ADD > EQ 3GM BASE/VIALM  
 > ADD > EQ 4GM BASE/VIALM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-18)

OINTMENT; OPHTHALMIC  
BACITRACIN-NEOMYCIN-POLYMYXIN  
 > ADD > AT BYK-GULDEN 400 UNITS/GM;EQ 3.5MG BASE/GM;  
 > ADD > AT 10,000 UNITS/GM  
 > ADD > BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE  
 > ADD > AT PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM;  
 > ADD > AT 10,000 UNITS/GM

BETAMETHASONE VALERATE (PAGE 3-20)

> DLT > /AEROSOL; TOPICAL/  
 > DLT > /VALISONE/  
 > DLT > /SCHERING/ 0.15%

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-25)

> DLT > /INJECTABLE; INJECTION/  
 > ADD > SOLUTION; INTRAPERITONEAL  
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER  
 > ADD > AT TRAVENOL LABS 25.7MG/100ML;1.5GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML  
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER  
 > ADD > AT TRAVENOL LABS 25.7MG/100ML;2.5GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML  
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER  
 > ADD > AT TRAVENOL LABS 25.7MG/100ML;4.25GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML  
INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER  
 > ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;1.5GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML  
INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER  
 > ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;2.5GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML  
INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER  
 > ADD > AT ABBOTT LABORATORIES 25.7MG/100ML;4.25GM/100ML;  
 > ADD > AT 5.08MG/100ML;538MG/100ML;448MG/100ML



**CALCIUM GLUCEPATE (PAGE 3-26)**

**INJECTABLE; INJECTION**  
**CALCIUM GLUCEPATE**  
**INTL MEDICATION SY**

**CHLORAMPHENICOL SODIUM SUCCINATE (PAGE 3-31)**

**INJECTABLE; INJECTION**  
**CHLORAMPHENICOL SODIUM SUCCINATE**  
**LYPHO-MED**  
**EQ 1GM BAS**

**CHLOROTHIAZIDE (PAGE 3-33)**

**TABLET; ORAL**  
**CHLOROTHIAZIDE**  
**BOLAR PHARMAC**

SYRUP; ORAL  
/HISTREY/  
/BONMAN.PHARMS/  
/ZMG/5ML/  
/ZMG/5ML/

**CHLORPROMAZINE HYDROCHLORIDE (PAGE 3-35)**

CHLORPROMAZINE HCL  
VANGUARD LABS/MWM  
WEST-WARD

**CHLORZOXAZONE (PAGE 3-37)**

TABLET; ORAL  
CHLORZOXAZONE  
CHELSEA LABORATORIES 250MGx

**CYCLOPHOSPHAMIDE (PAGE 3-44)**

INJECTABLE; INJECTION  
CYTOXAN  
HEAD JOHNSON/B-M  
1GM/VIALX  
2GM/VIALX

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

CYPROHEPTADINE HCL / PREMO PHARM TABS / LEMON

**DEXAMETHASONE (PAGE 3-47)**

TABLET; ORAL  
DEXAMETHASONE  
BP > ADD > ROXANE LABOR

**DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)**

INJECTABLE; INJECTION

DEXAMETHASONE

ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML

ADD >

ADD >

ADD >

ADD >

DEXAMETHASONE SODIUM PHOSPHATE

ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML

ADD >

ADD >

ADD >

ADD >

> DLT > /DEXBROMPHENIRAMINE MALEATE; PSEUDOPHEDRINE SULFATE/ (PAGE 3-49)

|                                  |       |
|----------------------------------|-------|
| TABLET, ORAL                     | > 0.1 |
| /DISPHROL                        | > 0.1 |
| /SCHEINING                       | > 0.1 |
| /2mg;60mg                        |       |
| TABLET, CONTROLLED RELEASE, ORAL | > 0.1 |
| /PRIXORAL                        | > 0.1 |
| /SCHEINING                       | > 0.1 |
| /6mg;120mg                       |       |

**DIAIRIZOATE MEGUMINE (PAGE 3-54)**

|                       |                           |    |         |
|-----------------------|---------------------------|----|---------|
| INJECTABLE; INJECTION | ANGIOVIST 282             | AP | < ADD > |
|                       | BERLEX/SCHERING AG        | AP | < ADD > |
|                       | UNOVIST MEGALUMINE D10/CI | AP | < ADD > |
|                       | BERLEX/SCHERING AG        | AP | < ADD > |
|                       | 602M                      | AP | < ADD > |

|                         |    |  |  |  |  |
|-------------------------|----|--|--|--|--|
| SOLUTION; URETHRAL      |    |  |  |  |  |
| URVOIST CYSTO           |    |  |  |  |  |
| BERLEX/SCHERING AG      | AT |  |  |  |  |
| 302M                    |    |  |  |  |  |
| URVOIST CYSTO PEDIATRIC |    |  |  |  |  |
| BERLEX/SCHERING AG      | AT |  |  |  |  |
| 302M                    |    |  |  |  |  |

DIATRIZOATE MEGGLUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION  
 > ADD > ANGIOVIST 292  
 > ADD > AP BERLEX/SCHERING AG 52%;82M  
 > ADD > ANGIOVIST 370  
 > ADD > AP BERLEX/SCHERING AG 66%;102M  
 SOLUTION; ORAL, RECTAL  
 > ADD > GASTROVIST  
 > ADD > AA BERLEX/SCHERING AG 66%;102M

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION  
 > ADD > UROVIST SODIUM 300  
 > ADD > AP BERLEX/SCHERING AG 502M

DIMENHYDRINATE (PAGE 3-57)

> DLT > /SUPPOSITORY; RECTAL/  
 > DLT > /DRAMINE/  
 > DLT > /SEARLE PHARMS/ /100MG/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-58)

CAPSULE; ORAL  
 DIPHENHYDRAMINE HCL  
 > DLT > /PREMO PHARM LABS/ /25MG/  
 > DLT > /50MG/

DOPAMINE HYDROCHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION  
 > ADD > DOPAMINE HCL  
 > ADD > AP ABBOTT LABORATORIES 80MG/MLM

DOXYCYCLINE HYCLATE (PAGE 3-61)

TABLET; ORAL  
 > ADD > DOXYCYCLINE HYCLATE  
 > ADD > AB BARR LABORATORIES EQ 100MG BASEM

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE (PAGE 3-62)

INJECTABLE; INJECTION  
 > DLT > /DURANEST W/ EPINEPHRINE/  
 > ADD > DURANEST

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-63)

INJECTABLE; INJECTION  
 > ADD > XYLOCAINE W/ EPINEPHRINE  
 ASTRA PHARM PRODS 0.005MG/ML;0.52M

ERGOLOID MESYLATES (PAGE 3-63)

TABLET; ORAL  
 > ADD > ERGOLOID MESYLATES  
 DANBURY PHARMACAL 1MGH  
 TABLET; SUBLINGUAL  
 > ADD > H.E.A.  
 > ADD > AA VANGARD LABS/MWM 0.5MGH  
 > ADD > AA 1MGH

> DLT > /ETHINYL ESTRADIOL; ETHINODIOL DIACETATE; FERROUS FUMARATE/  
 (PAGE 3-69)

> DLT > /TABLET; ORAL-28/  
 > DLT > /DENOLEN-FE-28/  
 > DLT > /SEARLE/SEARLE PHARMS/0.05MG;1MG;75MG/

> ADD > ETOMIDATE (PAGE 3-71)

> ADD > INJECTABLE; INJECTION  
 > ADD > AMIDATE  
 > ADD > ABBOTT LABORATORIES 2MG/MLM

FENFLURAMINE HYDROCHLORIDE (PAGE 3-71)

> ADD > TABLET, CONTROLLED RELEASE; ORAL  
 > ADD > PONDIMIN  
 > ADD > AH ROBINS 60MGH

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION  
 > ADD > ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER  
 > ADD > TRAVENOL LABS EQ 0.8MG BASE/MLM  
 > ADD > EQ 80MG BASE/100MLM

> ADD > GONADORELIN HYDROCHLORIDE (PAGE 3-77)

> ADD > INJECTABLE; INJECTION  
 > ADD > FACTREL  
 > ADD > AYERST LABS/AMHO EQ 0.1MG BASE/VIALM  
 > ADD > EQ 0.5MG BASE/VIALM





METHANTHELINE BROMIDE (PAGE 3-111)

> DLT > /INJECTABLE; INJECTION/  
> DLT > /BANTHINE/  
> DLT > /SEARLE/SEARLE PHARMS/50MG/VIAL/

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL  
METHYCLOTHIAZIDE  
> ADD > AB MYLAN PHARMS 2.5MGX  
> ADD > AB 5MGX

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION  
> ADD > AP METRO I.V.  
> ADD > AP AM MCGAW/AM HOSP 500MG/100MLX  
  
TABLET; ORAL  
METRONIDAZOLE  
> ADD > AB /LEMMON/ 250MG/  
> ADD > AB METRYL  
> ADD > AB LEMMON 250MG

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

> ADD > TABLET; ORAL  
> ADD > MINOCIN  
> ADD > LEDERLE LABS/AM CYAN EQ 50MG BASEX  
> ADD > EQ 100MG BASEX

NYSTATIN (PAGE 3-123)

OINTMENT; TOPICAL  
NYSTATIN  
> ADD > AT BYK-GULDEN 100,000 UNITS/GMX

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL  
OXYTETRACYCLINE HCL  
> DLT > AB /LEDERLE LABS/AM CYAN/EQ 250MG BASE/

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL  
PHENDIMETRAZINE TARTRATE  
> DLT > AA /CORP. LABORATORIES/ 35MG/  
> ADD > AA REID-PROVIDENT LABS 35MG  
> ADD > X-TROZINE  
> ADD > AA REXAR PHARMACAL 35MGX

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE, CONTROLLED RELEASE; ORAL  
X-TROZINE L.A.  
> ADD > BC REXAR PHARMACAL 105MGX

PENTERMINE HYDROCHLORIDE (PAGE 3-133)

TABLET; ORAL  
PENTERMINE HCL  
> DLT > AA /CORP. LABORATORIES/ 8MG/  
> ADD > TORA  
> ADD > AA REID-PROVIDENT LABS 8MG

> ADD > PINDOLOL (PAGE 3-135)

> ADD > TABLET; ORAL  
> ADD > VISKEN  
> ADD > SANDOZ PHARMS/SANDOZ 5MGX  
> ADD > 10MGX  
> ADD > 15MGX

PREDNISOLONE (PAGE 3-139)

TABLET; ORAL  
PREDNISOLONE  
> DLT > AB /PUREPAC/KALIPHARMA/ 5MG/

PROBENECID (PAGE 3-142)

TABLET; ORAL  
PROBENECID  
> DLT > AB /BEECHAM LABS/BEECHAM/ 500MG/

PROCHLORPERAZINE EDISYLATE (PAGE 3-144)

SYRUP; ORAL  
COMPAZINE  
> ADD > AA SK&F LABORATORIES EQ 5MG BASE/5ML  
> ADD > PROCHLORPERAZINE EDISYLATE  
> ADD > AA NATL PHARM MFG/BARRE EQ 5MG BASE/5MLX

PROMETHAZINE HYDROCHLORIDE (PAGE 3-145)

INJECTABLE; INJECTION  
> DLT > /PHENCEN-50/  
> DLT > AB /CENTRAL PHARMS/ 50MG/ML/



## PROPACACINE HYDROCHLORIDE (PAGE 3-146)

> ADD > AT  
SOLUTION/DROPS; OPHTHALMIC  
PARACACINE  
PRO PHARMA/STERI-MED 0.5%  
80MG/15ML

## PROPOXYPHENE HYDROCHLORIDE (PAGE 3-147)

> DLT > AA / 65MG /  
/PREP. PHARM. LABS /  
LEMON  
/ROXANE, LABORATORIES / 65MG /  
CAPSULE; ORAL  
PROPOXYPHENE HCL

## QUINIDINE GLUCONATE (PAGE 3-150)

> ADD > AB  
TABLET, CONTROLLED RELEASE; ORAL  
QUINIDINE GLUCONATE  
DANBURY PHARMACAL  
324MG

## SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)

> ADD > AT  
CREAM; VAGINAL  
SULNAC  
NMC LABORATORIES  
3.7%:2.86%:3.42%:0.64%  
3.7%:2.86%:3.42%:0.64%

## SULFINPYRAZONE (PAGE 3-162)

> ADD > AB  
CAPSULE; ORAL  
ANTURANE  
CIBA/CIBA-GEIGY  
200MG  
> ADD > AB  
SULFINPYRAZONE  
BARR LABORATORIES  
200MG  
> ADD > AB  
TABLET; ORAL  
SULFINPYRAZONE  
BARR LABORATORIES  
100MG

## TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-164)

> ADD > AP  
INJECTABLE; INJECTION  
AMERICAN  
AMERSHAM/RADIOCHEM  
N/A

## TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

> DLT >  
INJECTABLE; INJECTION  
TECHNETIUM TC 99M SULFUR COLLOID  
/SINCOB, INTL /  
/ZMT/INTL /

## THEOPHYLLINE (PAGE 3-168)

> DLT >  
/SLO-PHYLLIN-80 /  
/POONER, LABORATORIES / 80MG/15ML  
> ADD > AA  
SLO-PHYLLIN  
WILLIAM H RORER  
80MG/15ML  
TABLET; ORAL  
SLO-PHYLLIN

> DLT > BP / 100MG /  
/POONER, LABORATORIES / 100MG /  
> DLT > BP / 200MG /  
/POONER, LABORATORIES / 200MG /  
> ADD > BD  
WILLIAM H RORER  
100MG  
200MG  
TABLET, CONTROLLED RELEASE; ORAL  
THEOCONTIN  
PURDUE FREDERICK  
400MG

## TRIAMCINOLONE ACETONIDE (PAGE 3-173)

> ADD > AT  
CREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE  
PHARMAFAIR  
0.025%  
0.1%  
0.5%  
LOTION; TOPICAL  
KENALOG  
ER SQUIBB AND SONS  
0.025%  
0.1%  
TRIAMCINOLONE ACETONIDE  
NATL PHARM MFG/BARRE  
0.025%  
0.1%

## TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

> DLT >  
/TRIFAZINE /  
CONCENTRATE; ORAL  
TEP

## TROPICAMIDE (PAGE 3-178)

> ADD > AT  
SOLUTION/DROPS; OPHTHALMIC  
HYDRAGYL  
ALCON LABORATORIES  
1%  
TROPICAMIDE  
PRO PHARMA/STERI-MED 1%

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL

ATHROMBIN

|         |      |                     |        |
|---------|------|---------------------|--------|
| > DLT > | /BP/ | /PURDUE, FREDERICK/ | /5MG/  |
| > DLT > | /BP/ |                     | /10MG/ |
| > ADD > | BX   | PURDUE FREDERICK    | 5MG    |
| > ADD > | BX   |                     | 10MG   |

COUMADIN

|         |      |                     |         |
|---------|------|---------------------|---------|
| > DLT > | /BP/ | /ENDO, LABS/DUPONT/ | /2MG/   |
| > DLT > | /BP/ |                     | /2.5MG/ |
| > DLT > | /BP/ |                     | /5MG/   |
| > DLT > | /BP/ |                     | /7.5MG/ |
| > DLT > | /BP/ |                     | /10MG/  |
| > ADD > | BX   | ENDO LABS/DUPONT    | 2MG     |
| > ADD > | BX   |                     | 2.5MG   |
| > ADD > | BX   |                     | 5MG     |
| > ADD > | BX   |                     | 7.5MG   |
| > ADD > | BX   |                     | 10MG    |

PANWARFIN

|         |      |                        |         |
|---------|------|------------------------|---------|
| > DLT > | /BP/ | /ABBOTT, LABORATORIES/ | /2MG/   |
| > DLT > | /BP/ |                        | /2.5MG/ |
| > DLT > | /BP/ |                        | /5MG/   |
| > DLT > | /BP/ |                        | /7.5MG/ |
| > DLT > | /BP/ |                        | /10MG/  |
| > ADD > | BX   | ABBOTT LABORATORIES    | 2MG     |
| > ADD > | BX   |                        | 2.5MG   |
| > ADD > | BX   |                        | 5MG     |
| > ADD > | BX   |                        | 7.5MG   |
| > ADD > | BX   |                        | 10MG    |

WARFARIN SODIUM

|         |    |                      |        |
|---------|----|----------------------|--------|
| > ADD > | BX | BOLAR PHARMACEUTICAL | 2MGX   |
| > ADD > | BX |                      | 2.5MGX |
| > ADD > | BX |                      | 5MGX   |
| > ADD > | BX |                      | 7.5MGX |
| > ADD > | BX |                      | 10MGX  |



ADDENDUM  
DESI PENDING LIST  
CUMULATIVE SUPPLEMENT NUMBER 1 / AUGUST '62 & SEPTEMBER '62

CURRENT STATUS - 'EXEMPT' (COURT ORDER)

|       |                      |                    |       |
|-------|----------------------|--------------------|-------|
| > ADD | DIPYRIDAMOLE         | SUPERPHARM         | > ADD |
| > ADD | ISOSORBIDE DINITRATE | INWOOD LABS/FOREST | > ADD |
| > ADD | METHANDROSTENOLONE   | PAR PHARMACEUTICAL | > ADD |
| > ADD | NITROGLYCERIN        | VITARINE/WEST CHEM | > ADD |
| > ADD | NITROSTAL            | PARKE-DAVIS/M-L    | > ADD |
| > ADD | NITROGLYCERIN        |                    | > ADD |

# SUBSCRIPTION FORM

## APPROVED PRESCRIPTION DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 3RD EDITION (1982)

MAIL TO:

DATE:

Superintendent of Documents  
Government Printing Office  
Washington, DC 20402  
(202) 783-3238

PURCHASER:

SHIP TO:  
(if different than purchaser)

CONTACT:

TELEPHONE (Include Area Code)

### METHOD OF PAYMENT

☐ Charge my GPO Account No. \_\_\_\_\_  
☐ Purchase Order Number \_\_\_\_\_  
☐ Check enclosed for \$ \_\_\_\_\_  
 (Make check payable to Superintendent of Documents)

AUTHORIZING  
SIGNATURE

DATE:

| DESCRIPTION  | QUANTITY | UNIT PRICE | TOTAL PRICE |
|--|----------|------------|-------------|
| The 3rd Edition will be published in October, 1982. Subscription includes the Approved Prescription Drug Products List and monthly Cumulative Supplements. |          |            |             |
| DOMESTIC   |          | @ \$80.00  | \$          |
| FOREIGN  |          | @ \$100.00 | \$          |
| ENTER TOTAL  |          |            | \$          |



